We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
-5.72%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$322M
AUM Growth
-$34.8M
Cap. Flow
-$3.33M
Cap. Flow %
-1.03%
Top 10 Hldgs %
62.73%
Holding
76
New
14
Increased
20
Reduced
18
Closed
19

Top Buys

Rank Stock Value
1
ENSG icon
The Ensign Group
ENSG
+$14.9M
2
GSK icon
GSK
GSK
+$11.9M
3
ASND icon
Ascendis Pharma A/S
ASND
+$11.2M
4
NVST icon
Envista
NVST
+$8.88M
5
DXCM icon
DexCom
DXCM
+$6.92M

Top Sells

Rank Stock Value
1
RCM
R1 RCM Inc. Common Stock
RCM
+$23.3M
2
EHTH icon
eHealth
EHTH
+$12.3M
3
RDUS
Radius Health, Inc.
RDUS
+$8.96M
4
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$8.38M
5
NUVA
NuVasive, Inc.
NUVA
+$5.37M

Sector Composition

Rank Sector Weight
1 Healthcare 90.47%
2 Real Estate 4.59%
3 Industrials 2.01%
4 Communication Services 1.04%
5 Miscellaneous 1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LUMO
51
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$434K 0.13%
+30,331
New +$445K
PFNX
52
DELISTED
Pfenex Inc.
PFNX
$405K 0.13%
47,968
-33,000
-41% -$239K
CVM icon
53
PUT
CEL-SCI Corp
CVM
$27.4M
$383K 0.12%
+1,427
New +$334K
ALBO
54
DELISTED
Albireo Pharma Inc
ALBO
$361K 0.11%
18,029
– –
AIMT
55
PUT
DELISTED
Aimmune Therapeutics
AIMT
$209K 0.07%
+10,000
New +$204K
AIMT
56
CALL
DELISTED
Aimmune Therapeutics
AIMT
$191K 0.06%
+9,100
New +$186K
AKRX
57
DELISTED
Akorn Inc
AKRX
$153K 0.05%
40,242
-91,398
-69% -$327K
BCRX icon
58
CALL
BioCryst Pharmaceuticals
BCRX
$2.51B
– –
-101,800
Closed -$386K
CNC icon
59
Centene
CNC
$32B
– –
-99,600
Closed -$5.22M
CYCN icon
60
Cyclerion Therapeutics
CYCN
$17.7M
– –
-946
Closed -$217K
ELV icon
61
Elevance Health
ELV
$85.5B
– –
-10,000
Closed -$2.82M
HUM icon
62
Humana
HUM
$46.3B
– –
-10,000
Closed -$2.66M
NGNE icon
63
Neurogene
NGNE
$732M
– –
-3,686
Closed -$174K
PTCT icon
64
PTC Therapeutics
PTCT
$5.85B
– –
-48,600
Closed -$2.19M
SRPT icon
65
Sarepta Therapeutics
SRPT
$2.2B
– –
-16,554
Closed -$2.52M
CBAY
66
DELISTED
Cymabay Therapeutics
CBAY
– –
-84,296
Closed -$604K
NUVA
67
DELISTED
NuVasive, Inc.
NUVA
– –
-91,798
Closed -$5.37M
PRVB
68
DELISTED
Provention Bio, Inc. Common Stock
PRVB
– –
-73,661
Closed -$891K
ARNA
69
DELISTED
Arena Pharmaceuticals Inc
ARNA
– –
-73,501
Closed -$4.31M
MYOK
70
DELISTED
MyoKardia, Inc. Common Stock
MYOK
– –
-56,652
Closed -$2.84M
FOMX
71
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
– –
-263,390
Closed -$627K
DERM
72
DELISTED
Dermira, Inc.
DERM
– –
-399,874
Closed -$3.82M
MDCO
73
DELISTED
Medicines Co
MDCO
– –
-57,200
Closed -$2.09M
GHDX
74
DELISTED
Genomic Health, Inc.
GHDX
– –
-38,403
Closed -$2.23M
ZGNX
75
CALL
DELISTED
Zogenix, Inc.
ZGNX
– –
-104,300
Closed -$4.98M
1 2
3
4

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q3 2019 Portfolio in Review

As of Q3 2019, Eversept Partners held 76 positions worth $322M, down 9.7% from $357M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Eversept Partners's Q3 2019 filing shows 14 new, 20 increased, 18 reduced and 19 closed positions. Its largest new stake was Envista: 318,000 shares worth $8.87M. The largest sale was R1 RCM Inc. Common Stock, an estimated $23.3M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 82% a quarter earlier, followed by Real Estate and Industrials.

  • Eversept Partners's largest Q3 2019 buy was Envista: 318,000 shares worth $8.87M.
  • Eversept Partners added most to The Ensign Group in Q3 2019, an estimated $14.9M increase.
  • Eversept Partners's biggest Q3 2019 reduction was R1 RCM Inc. Common Stock, cutting an estimated $23.3M.
  • Eversept Partners fully exited NuVasive, Inc. in Q3 2019, selling an estimated $5.37M.
  • Eversept Partners's ten largest holdings make up 63% of its $322M portfolio in Q3 2019.
  • Eversept Partners opened 14 new positions and closed 19 in Q3 2019.
  • Eversept Partners's portfolio value fell 9.7% quarter-over-quarter to $322M.

Based on Eversept Partners's 13F filing for Q3 2019, filed 13 Nov 2019.